WASHINGTON (AP) — The Trump administration opted last summer not to lock in a chance to buy millions of additional doses of one of the leading coronavirus vaccine contenders. That decision could delay the delivery of a second batch of doses until manufacturer Pfizer fulfills other international contracts. The revelation